학술논문

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Document Type
article
Source
Science Translational Medicine. 9(373)
Subject
Biomedical Imaging
Gene Therapy
Brain Cancer
Cancer
Immunization
Vaccine Related
Genetics
Biotechnology
Orphan Drug
Bioengineering
Brain Disorders
Rare Diseases
Development of treatments and therapeutic interventions
5.2 Cellular and gene therapies
Aged
Brain Neoplasms
Female
Gene Expression
Genes
Reporter
Genetic Therapy
Glioma
Humans
Immunotherapy
Interleukin-13
Male
Middle Aged
Neoplasm Recurrence
Local
Positron-Emission Tomography
Prospective Studies
Receptors
Antigen
T-Cell
T-Lymphocytes
Cytotoxic
Thymidine Kinase
Biological Sciences
Medical and Health Sciences
Language
Abstract
High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using CD8+ cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex virus type 1 thymidine kinase (HSV1-TK) and interleukin-13 (IL-13) zetakine chimeric antigen receptor (CAR), is a treatment strategy with considerable potential. To optimize this and related immunotherapies, it would be helpful to monitor CTL viability and trafficking to glioma cells. We show that noninvasive positron emission tomography (PET) imaging with 9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine ([18F]FHBG) can track HSV1-tk reporter gene expression present in CAR-engineered CTLs. [18F]FHBG imaging was safe and enabled the longitudinal imaging of T cells stably transfected with a PET reporter gene in patients. Further optimization of this imaging approach for monitoring in vivo cell trafficking should greatly benefit various cell-based therapies for cancer.